Tucatinib
Products Tucatinib was approved in the United States and many countries in 2020 in film-coated tablet form (Tukysa). Structure and properties Tucatinib (C26H24N8O2, Mr = 480.5 g/mol) Effects Tucatinib has antitumor and antiproliferative properties. The effects are due to inhibition of HER2 tyrosine kinase. The half-life is approximately 8.5 hours. Indications In combination with trastuzumab … Tucatinib
